Infections Due to Carbapenem-Resistant Bacteria in Patients With Hematologic Malignancies

In developed countries, hematological malignancies (HM) account for 8 to 10% of cancers diagnosed annually and one-third of patients with HM (HMP) are expected to die from their disease. The former wide spectrum “magic bullet,” imipenem, has been ousted by the emergence of carbapenem resistant (CR)...

Full description

Bibliographic Details
Main Authors: Rym Lalaoui, Emilie Javelle, Sofiane Bakour, Carles Ubeda, Jean-Marc Rolain
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-07-01
Series:Frontiers in Microbiology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fmicb.2020.01422/full